Anti-RPS6KA3 / Ribosomal protein S6 kinase alpha-3

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. RPS6KA3 antibody detects Ribosomal protein S6 kinase alpha-3, a serine/threonine kinase that functions as a key effector in the MAPK signaling pathway. Also known as p90RSK2, this kinase transmits signals from extracellular stimuli to regulate cell growth, survival, and gene expression. The RPS6KA3 antibody is widely used in studies of neuronal development, signal transduction, and cancer biology.RPS6KA3 is encoded by the RPS6KA3 gene located on the X chromosome (Xp22.12). The protein is approximately 83 kilodaltons and contains two distinct kinase domains: an N-terminal kinase domain responsible for substrate phosphorylation and a C-terminal kinase domain that mediates activation through phosphorylation by ERK1/2. This dual-kinase configuration enables fine-tuned regulation of RPS6KA3 activity in response to mitogenic and stress stimuli.The RPS6KA3 antibody detects the full-length kinase as well as phosphorylated intermediates in western blot and immunofluorescence assays. RPS6KA3 phosphorylates transcription factors such as CREB, c-Fos, and histone H3, linking MAPK activation to transcriptional control. It also phosphorylates cytoplasmic substrates involved in mRNA translation and cytoskeletal rearrangement. The protein plays a central role in synaptic plasticity and long-term memory formation, highlighting its importance in neural signaling.Mutations in RPS6KA3 cause Coffin-Lowry syndrome, an X-linked developmental disorder characterized by cognitive impairment and skeletal abnormalities. Disruption of RPS6KA3 signaling leads to defective ERK pathway regulation, impaired neuronal differentiation, and altered gene expression. Overactivation of RPS6KA3, on the other hand, contributes to oncogenic transformation through hyperactive MAPK signaling, promoting cell proliferation and resistance to apoptosis.Because of its role in growth and survival pathways, RPS6KA3 serves as a potential therapeutic target in cancer and neurological disease. The RPS6KA3 antibody from NSJ Bioreagents is validated for western blot, immunofluorescence, and kinase activity assays, supporting detailed research into MAPK signaling, transcriptional regulation, and disease-related kinase mechanisms.